Vyome Holdings, Inc

Listed Company

HINDCIK 0001427570NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$319.7K

Net Income

$-10.26M

Total Assets

$6.50M

Equity

$3.76M

Shares Out

7.02M

Op. Cash Flow

$-3.75M

Business

Vyome Holdings, Inc is a medical technology and therapeutics company combining ReShape Lifesciences’ obesity and metabolic disease portfolio with Vyome’s immuno‑inflammatory assets. It offers minimally invasive weight‑loss and metabolic health products and therapies, including the FDA‑approved Lap‑Band system, Lap‑Band 2.0 FLEX, the Obalon gas‑filled balloon system, calibration tubes and a diabetes neuromodulation (DBSN) device under development. The company operates product development, regulatory/compliance, commercialization and clinical research functions across its device and bioelectronic therapy offerings. It distributes through direct patient marketing, qualified surgical centers, field sales, and international agents, distributors and strategic partners.

Summary from filing dated 2025-04-04

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	319,714	256,944	—	—	—
Cost of goods sold	−100,943	−61,974	3	4	5
Gross profit	218,771	194,970	6	7	8
Depreciation and amortization	11,985	17,347	—	—	—
Selling, general and administrative	2	898,572	8	14	9
Research and development	588,258	285,391	2	3	2
Transactional fees	8	—	—	—	—
Total operating expenses	11	1	21	53	66
Operating loss	−10	−1	−15	−46	−58
Interest expense	−146,641	−206,004	—	—	—
Other income(loss), net	90,987	3,814	—	—	—
Fair value adjustment	30,511	−238,931	−4	—	—
Total other income (expense), net	−25,143	−441,121	—	—	—
Net loss	−10	−1	—	—	—
Net loss attributable to non-controlling interest	−215,706	—	—	—	—
Net loss attributable to owners of Vyome Holdings, Inc.	−10	−1	−11	—	—
Foreign currency translation adjustments	−25,694	1,127	—	—	—
Total comprehensive loss	−11	−1	—	—	—
Loss per share basic (in Dollars per share)	−4.86	−6,001	−110.87	−108.9	−288.97
Loss per share diluted (in Dollars per share)	−4.86	−6,001	−110.87	−108.9	−288.97
Weighted average number of shares outstanding basic (in Shares)	2	241	102,707	424,390	218,522
Weighted average number of shares outstanding diluted (in Shares)	2	241	102,707	424,390	218,522

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2026 2026-12-31	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	—	5	101,904	4	4
Deferred offering costs	—	—	111,415	—	—
Prepaid expenses	—	336,687	9,039	—	—
Other current assets	—	119,301	79,688	—	—
Total current assets	—	5	302,046	10	10
Property and equipment, net	—	46,393	59,179	60,000	698,000
Intangible asset - shell company	—	314,191	314,191	—	—
Goods and service tax and other credits receivable	—	601,537	646,758	—	—
Prepaid insurance long term portion	—	67,307	—	—	—
Right-of-use of asset, net	—	29,428	59,387	250,000	171,000
Total non-current assets	—	1	1	—	—
Total assets	—	6	1	11	11
Accounts payable and accrued expenses	—	1	965,607	—	—
Due to Affiliates	—	204,562	129,346	—	—
Operating lease liability - current portion	31,258	31,258	28,024	111,000	171,000
Salary and post-employment benefits payable	—	870,822	919,440	—	—
Other current liabilities	—	341,835	107,937	—	—
Convertible debt - current portion	—	—	4	—	—
Total current liabilities	—	3	6	4	7
Operating lease liability - net of current portion	—	—	32,830	151,000	—
Total non-current liabilities	—	—	32,830	—	—
Total liabilities	—	3	6	4	7
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock, 300,000,000 VHI shares authorized, 5,919,337 and 0 shares issued and outstanding at December 31, 2025 and 2024, respectively	—	5,919	—	—	1,000
Preferred stock of VTI, 16,000,000 shares authorized, 0 and 3,076 shares issued and outstanding as of December 31, 2025 and 2024, respectively	—	—	3	—	—
Additional paid in capital	—	90	51	642	628
Non-controlling interest in VTI; 20,000,000 common shares authorized, 1,481,598 and 386 shares issued and outstanding at December 31, 2025 and December 31, 2024	—	1	1	—	—
Accumulated deficit	—	−88	−55	−636	−624
Accumulated other comprehensive loss	—	−78,864	−53,170	−88,000	−88,000
Total stockholders equity (deficit)	—	4	−4	−6	—
Total liabilities and stockholders equity (deficit)	—	6	1	11	11

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
(Gain) loss on fair value adjustment of convertible debt	−30,511	238,931	—	—	—
Non-cash accrued interest expense	130,659	186,659	—	—	—
Stock compensation expense - stock options	577,128	—	766,000	2	12
Stock compensation expense common stock	6	—	—	—	—
Prepaid expenses and other current assets	−434,568	64,463	−172,000	1	−76,000
Other assets	75,982	78,742	—	—	—
Accounts payable and accrued expenses	171,342	−58,861	−3	448,000	−1
Due to Affiliates	75,216	95,972	—	—	—
Post employment benefits	−48,618	197,935	—	—	—
Other liabilities	200,551	12,137	—	—	—
Net cash used in operating activities	−4	−614,136	−17	−22	−15
Net proceeds from sale of fixed assets	—	315	—	—	—
Net cash used in investing activities	—	315	−10,000	−92,000	2
Proceeds from issuance of convertible debt	191,253	667,009	—	—	—
Proceeds from promissory note issued by Reshape	600,000	—	—	—	—
Proceeds from sale of common stock pursuant to ATM	1	—	13	639,000	—
Proceeds from sale of common stock under Concurrent Financing, net of costs of $100,000 and deferred offering costs of $111,415	7	—	—	—	—
Proceeds from exercise of warrants	6,009	—	4	2	46
Advance from affiliates	—	30,942	—	—	—
Net cash provided by financing activities	9	697,951	18	3	33
Effect of exchange rate changes on cash and cash equivalents	−25,694	1,127	—	4,000	29,000
Net increase in cash and cash equivalents	5	85,257	604,000	−19	20
Shares issued in settlement of liability to vendor	—	2	—	—	—
Exchange of accrued fees to director for stock options	—	450,000	—	—	—
Exchange of accrued compensation for stock options	—	665,232	—	—	—
Incremental fair value of exchange of VTI preferred shares for new series of VTI preferred shares	19	—	—	—	—
Conversion of preferred shares of VTI to common stock of VTI	1,242	—	—	—	—
Net liabilities assumed upon Merger with Reshape	149,735	—	—	—	—
Conversion of debt into common stock	4	—	—	—	—
Fair value of issuance of warrants to preferred shareholders	2	—	—	—	97,000
Reclass of deferred offering costs to additional paid in capital	111,415	—	—	—	—
Exchange of entitlement shares for common shares of VHI	29,572	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro